Overdose is the leading cause of accidental death in North America for people under 50
Be part of the solution.
Join Our Mailing List
Addiction Affects Us All
Percentage of Canadian adults suffering from addiction
People receiving treatment for addiction in treatment centres
Relapse rate associated with current treatment modalities
Annual Increase in Substance Abuse Deaths worldwide since 1999
Increase in overdose deaths amongst First Nations communities in BC (2019-2020)
$ 2.93 Trillion
The cost of the Opioid Crisis in the USA from 2015-2018
Ibogaine is a naturally-occurring molecule derived from the root bark of the iboga tree and other plants. It is a potent and serious medical psychedelic which has addiction interrupting properties.
Ibogaine has a “Prescription Drug List” status in Canada (vs. Schedule 1 in the US) facilitating research and development toward medicalization.
Ibogaine targets multiple receptors across multiple sites in the brain and metabolizes into noribogaine, a serotonin re-uptake inhibitor that remains in the body for 1-4 months, associated with elimination of addictive cravings.
What is Ibogaine?
How does it work?
Ibogaine targets multiple receptor sites in the brain when It manages dopamine and serotonin circuits & may stimulate new brain cell growth. This creates an opportunity to change behaviours. Paired with our treatment protocol, Ibogaine alleviates withdrawal symptoms and interrupts the process of active addiction.
Our mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery.
While seeking to move Ibogaine through Clinical Trials in Canada, we are building a network of holistic recovery clinics and a state of the art treatment program centred around new treatment modalities.
Chief Executive Officer
Nick Karos, Chief Executive Officer / Director of Capital Markets
As Director of Capital Markets, Nick Karos is a seasoned financier based in Los Angeles. His background includes senior roles with US investment banks and as CEO of Private Trading Group. Mr. Karos is focused on expanding awareness of UI in the US-based investment community including institutional investors, family offices, high net worth individuals and investment advisors, securing sources of expansion capital, as well as identifying business development opportunities in the addiction treatment industry.
Chief Financial Officer
Greg Leavens – Chief Financial Officer
Greg Leavens, CPA CA – a Calgary based financial executive (past CFO and Controller roles) with 30 years experience in public accounting and industry, including the oil & gas exploration / production and service sectors. Greg started his career with KPMG, and has extensive experience in leadership, strategic planning, due diligence reviews, financing, forecasting, financial reporting, treasury and risk management, and regulatory compliance.
Dr. Ian Rabb
Chief Clinics Officer
Dr Ian Rabb – Chief Clinics Officer
Dr Ian Rabb is one of the most recognized and respected leaders in Addiction Treatment in Canada today. Dr. Ian Rabb is a certified Interventionist and addictions specialist who has helped thousands of people overcome addiction.
Colleen Clandening – VP Operations
Colleen Clandening utilizes her passion to give back and her expertise in business development to facilitate true collaboration and win win outcomes. Colleen is a true visionary and entrepreneur. Colleen upholds the core value of “shared leadership” throughout her career. Colleen works across multiple sectors including; entertainment, design build, retail, manufacturing, real estate, government, and non- profits. She is committed to fitness...physical, mental and spiritual.
Director of Clinical Services
Hirpal Hundial – Director, Clinical Services
Hirpal has over 30 years of health care leadership experience focused on clinical practice in high acuity settings, curriculum development and delivery for registered nurses and regularly serves the Supreme Court of B.C. as an expert on standard of care. Hirpal has worked closely with Health Canada to facilitate upcoming clinical trials for ibogaine in Canada. Hirpal is a graduate of the University of British Columbia with her Master of Science in Nursing (Hons) and is certified by the Canadian Patient Safety Institute. Her recent research on critical thinking in the face of complexity has been internationally recognized. Hirpal is committed to developing more comprehensive and holistic systems of care for those suffering from addiction.
Communications & Investor Relations
Dugan Selkirk – Communications & Investor Relations
Dugan has enjoyed a 15 year entrepreneurial career including founding roles in media and health companies, he began consulting to start-ups to help develop their go to market strategy and attract financing to implement. Dugan is an Exempt Market Dealing Rep, and a CFA Candidate. He also operates a developmental lending program for entrepreneurs with disabilities, many of whom experience mental health and addiction challenges.